Further approved symptomatic therapies against PD include monoamine oxidase B (MOA-B) and catechol-o-methyltransferase (COMT) inhibitors for suppressing the metabolism of endogenous dopamine, as well as deep brain stimulation (DBS) [15]. Here, COMT is linked to Parkinson disease.